Announcement

Collapse
No announcement yet.

Transpl Infect Dis. Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Transpl Infect Dis. Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient


    Transpl Infect Dis. 2020 May 14:e13326. doi: 10.1111/tid.13326. [Epub ahead of print]
    Interleukin-6 Receptor Antagonist Therapy to Treat SARS-CoV-2 Driven Inflammatory Syndrome in a Renal Transplant Recipient.


    Allam SR1,2, Dao A2, Madhrira MM1,2, Antiporta PB3, Nair RR4, Guiteau JJ2, Reyad AI2.

    Author information




    Abstract

    Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a pandemic that is evolving rapidly at present with unprecedented global health and societal implications. Herein, we report a case of successful treatment of SARS-CoV-2 induced inflammatory syndrome by utilization of the interleukin-6 receptor antagonist (IL-6Ra) tocilizumab.
    This article is protected by copyright. All rights reserved.



    PMID:32406985DOI:10.1111/tid.13326

Working...
X